| Robert F Mazzuca, DO | |
|
501 Fifth St, Ste A, Atco, NJ 08004 | |
| (856) 768-2758 | |
| (856) 768-8364 |
| Full Name | Robert F Mazzuca |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 44 Years |
| Location | 501 Fifth St, Atco, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831163237 | NPI | - | NPPES |
| 0090878001 | Other | AMERIHEALTH | |
| 1909401 | Medicaid | NJ | |
| J1887 | Other | HORIZON | |
| 013463 | Other | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MB39135 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocare Llc | 3678562188 | 288 |
News Archive
Are you tired? A new study of young and middle-aged adults shows it could be happening because of the way society functions in your part of the world.
In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD - a major drawback with the old technology.
Practice Fusion Inc., the fastest growing electronic health record community for physicians in the United States, today announced a partnership with BioReference Laboratories, Inc. (NASDAQ:BRLI), the third largest full service laboratory in the country. The companies will collaborate to distribute Practice Fusion's EHR to interested BioReference physicians and will integrate BioReference lab results into the Practice Fusion's system.
Quintiles today announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.
QLT Inc. ("QLT" or the "Company") today announced that it has restructured its agreement with Novartis Pharma AG ("Novartis") to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive U.S. rights to the Visudyne(R) patents to sell and market Visudyne in the U.S. Visudyne, a photosensitizer co-developed with Novartis, is approved worldwide for the treatment of a form of wet age-related macular degeneration ("AMD"), the leading cause of legal blindness in people over the age of 55 in North America and Europe.
› Verified 9 days ago
| Entity Name | Advocare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770538696 PECOS PAC ID: 3678562188 Enrollment ID: O20040510001217 |
News Archive
Are you tired? A new study of young and middle-aged adults shows it could be happening because of the way society functions in your part of the world.
In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD - a major drawback with the old technology.
Practice Fusion Inc., the fastest growing electronic health record community for physicians in the United States, today announced a partnership with BioReference Laboratories, Inc. (NASDAQ:BRLI), the third largest full service laboratory in the country. The companies will collaborate to distribute Practice Fusion's EHR to interested BioReference physicians and will integrate BioReference lab results into the Practice Fusion's system.
Quintiles today announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.
QLT Inc. ("QLT" or the "Company") today announced that it has restructured its agreement with Novartis Pharma AG ("Novartis") to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive U.S. rights to the Visudyne(R) patents to sell and market Visudyne in the U.S. Visudyne, a photosensitizer co-developed with Novartis, is approved worldwide for the treatment of a form of wet age-related macular degeneration ("AMD"), the leading cause of legal blindness in people over the age of 55 in North America and Europe.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert F Mazzuca, DO 501 Fifth St, Ste A, Atco, NJ 08004 Ph: (856) 768-2758 | Robert F Mazzuca, DO 501 Fifth St, Ste A, Atco, NJ 08004 Ph: (856) 768-2758 |
News Archive
Are you tired? A new study of young and middle-aged adults shows it could be happening because of the way society functions in your part of the world.
In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD - a major drawback with the old technology.
Practice Fusion Inc., the fastest growing electronic health record community for physicians in the United States, today announced a partnership with BioReference Laboratories, Inc. (NASDAQ:BRLI), the third largest full service laboratory in the country. The companies will collaborate to distribute Practice Fusion's EHR to interested BioReference physicians and will integrate BioReference lab results into the Practice Fusion's system.
Quintiles today announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.
QLT Inc. ("QLT" or the "Company") today announced that it has restructured its agreement with Novartis Pharma AG ("Novartis") to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive U.S. rights to the Visudyne(R) patents to sell and market Visudyne in the U.S. Visudyne, a photosensitizer co-developed with Novartis, is approved worldwide for the treatment of a form of wet age-related macular degeneration ("AMD"), the leading cause of legal blindness in people over the age of 55 in North America and Europe.
› Verified 9 days ago
Dr. Pasquale D Vassalluzzo, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 78 Virginia Dr, Atco, NJ 08004 Phone: 856-336-2842 |